title: [Evaluation of immunity in elderly patients with unresectable gastric cancer receiving S-1/Lentinan combination chemotherapy].
abstract: OBJECTIVE
  This retrospective study evaluated immunity in elderly patients with unresectable gastric cancer receiving S-1/ Lentinan combination chemotherapy.
  
  
  METHODS
  This study included 10 patients aged≥70 years with unresectable gastric cancer who received S-1/Lentinan combination chemotherapy between October 2008 and December 2012. All patients gave written informed consent. Immune parameters for regulatory T cell(Treg)ratio, prostaglandin E2(PGE2), C3, CH50, and granulocyte/lymphocyte ratio were measured before chemotherapy initiation and at 7 weeks after it. Clinicopathological or immune parameters affecting overall survival(OS)were consequently evaluated.
  
  
  RESULTS
  A high Treg ratio(p=0.02) and low PGE2(p=0.05)levels at 7 weeks after chemotherapy and a decrease in the Treg ratio(p=0.02)were found to be significant favorable factors affecting OS.
  
  
  CONCLUSIONS
  The outcome of elderly patients with unresectable gastric cancer receiving S-1/Lentinan combination chemotherapy seemed to be correlated with the change in immunity.
authors.affiliation: Dept. of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University.
authors.forename: Minoru
authors.initials: M
authors.lastname: Fukuchi
authors.forename: Erito
authors.initials: E
authors.lastname: Mochiki
authors.forename: Toru
authors.initials: T
authors.lastname: Ishiguro
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Tsuji
authors.forename: Okihide
authors.initials: O
authors.lastname: Suzuki
authors.forename: Jun
authors.initials: J
authors.lastname: Sobajima
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Baba
authors.forename: Youichi
authors.initials: Y
authors.lastname: Kumagai
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Ishibashi
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003176:Complement C3 / Q000276:immunology; D015232:Dinoprostone / Q000276:immunology; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007912:Lentinan / Q000008:administration & dosage; D008297:Male; D010094:Oxonic Acid / Q000008:administration & dosage; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D003176:Complement C3; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D007912:Lentinan; D010094:Oxonic Acid; D015232:Dinoprostone